Page 21 - Read Online

Page 10 of 12 Ruff et al. Hepatoma Res 2023;9:17 https://dx.doi.org/10.20517/2394-5079.2023.18

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2023.

REFERENCES
1. Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev
2021;95:102170. DOI PubMed
2. Cardinale V, Semeraro R, Torrice A, et al. Intra-hepatic and extra-hepatic cholangiocarcinoma: new insight into epidemiology and risk
factors. World J Gastrointest Oncol 2010;2:407-16. DOI PubMed PMC
3. Primrose JN, Fox RP, Palmer DH, et al; BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer
(BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol 2019;20:663-73. DOI
4. Buettner S, van Vugt JL, IJzermans JN, Groot Koerkamp B. Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther
2017;10:1131-42. DOI PubMed PMC
5. Squires MH, Cloyd JM, Dillhoff M, Schmidt C, Pawlik TM. Challenges of surgical management of intrahepatic cholangiocarcinoma.
Expert Rev Gastroenterol Hepatol 2018;12:671-81. DOI PubMed
6. Valle J, Wasan H, Palmer DH, et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract
cancer. N Engl J Med 2010;362:1273-81. DOI
7. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev
Clin Oncol 2018;15:95-111. DOI PubMed PMC
8. Brown ZJ, Ruff SM, Pawlik TM. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy. Expert Rev Anticancer
Ther 2023;23:257-64. DOI PubMed
9. Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep
2017;19:2. DOI PubMed
10. Masarone M, Persico M. Hepatitis c virus infection and non-hepatocellular malignancies in the daa era: a systematic review and meta-
analysis. Liver Int 2019;39:1292-306. DOI
11. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T. Risk factors for intrahepatic cholangiocarcinoma: a possible role of
hepatitis B virus. J Viral Hepat 2010;17:742-8. DOI PubMed PMC
12. Kubo S, Takemura S, Tanaka S, et al. Occupational cholangiocarcinoma caused by exposure to 1,2-dichloropropane and/or
dichloromethane. Ann Gastroenterol Surg 2018;2:99-105. DOI PubMed PMC
13. Tao LY, Cai L, He XD, et al. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Am Surg ;2010.76:p. 1210-3. PubMed
14. Moro A, Mehta R, Sahara K, et al. The impact of preoperative CA19-9 and CEA on outcomes of patients with intrahepatic
cholangiocarcinoma. Ann Surg Oncol 2020;27:2888-901. DOI
15. Valls C, Gumà A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000;25:490-6. DOI
16. Seo N, Kim DY, Choi JY. Cross-sectional imaging of intrahepatic cholangiocarcinoma: development, growth, spread, and prognosis.
AJR Am J Roentgenol 2017;209:W64-75. DOI PubMed
17. Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver 2017;11:13-26. DOI PubMed PMC
18. Fábrega-Foster K, Ghasabeh MA, Pawlik TM, Kamel IR. Multimodality imaging of intrahepatic cholangiocarcinoma. Hepatobiliary
Surg Nutr 2017;6:67-78. DOI PubMed PMC
19. Fujita N, Asayama Y, Nishie A, et al. Mass-forming intrahepatic cholangiocarcinoma: enhancement patterns in the arterial phase of
dynamic hepatic CT - correlation with clinicopathological findings. Eur Radiol 2017;27:498-506. DOI
20. Hewitt DB, Brown ZJ, Pawlik TM. Surgical management of intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther
2022;22:27-38. DOI PubMed
18 18
21. Lamarca A, Barriuso J, Chander A, et al. F-fluorodeoxyglucose positron emission tomography ( FDG-PET) for patients with biliary
tract cancer: Systematic review and meta-analysis. J Hepatol 2019;71:115-29. DOI
22. Spolverato G, Vitale A, Cucchetti A, et al. Can hepatic resection provide a long-term cure for patients with intrahepatic
cholangiocarcinoma? Cancer 2015;121:3998-4006. DOI
23. Lamarca A, Edeline J, McNamara MG, et al. Current standards and future perspectives in adjuvant treatment for biliary tract cancers.
Cancer Treat Rev 2020;84:101936. DOI
24. Zhang XF, Bagante F, Chakedis J, et al. Perioperative and long-term outcome for intrahepatic cholangiocarcinoma: impact of major
versus minor hepatectomy. J Gastrointest Surg 2017;21:1841-50. DOI
25. Le Roy B, Gelli M, Pittau G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma. Br J Surg